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ABSTRACT 
Background: Patients with inflammatory bowel disease have a number of worries and 
concerns related to the disease, and in comparison with a general population their 
health-related quality of life is impaired. These patients need disease-related 
information and education. However, it remains unclear how this information should be 
provided in order to decrease their worries and concerns, and improve their health-
related quality of life. Disease activity is one of the most important factors for reduced 
health-related quality of life. Therefore it is also important to assess more information 
about trigger factors for relapses in inflammatory bowel disease.  
Aim: The general aim of this thesis was to gain scientific evidence about worries and 
concerns, health-related quality of life, and trigger factors for relapses, and to develop 
and evaluate an education programme. 
Method: In all four studies the patients included were diagnosed with inflammatory 
bowel disease, and in remission. In Study I, 93 patients were included and randomized 
to an intervention group or a control group. The intervention group attended a group-
based education programme. Health-related quality of life was measured at baseline 
and after six months, by using four questionnaires. The intervention group also 
completed the questionnaires after one month. In Study II, 197 patients were included 
and divided into a Crohn’s disease group and an ulcerative colitis group. Each group 
was also divided into separate groups according to whether the patients had short 
disease duration or long disease duration. Health-related quality of life was measured 
using four questionnaires. In Study III, a sample of 195 patients was included. They 
filled in the RFIPC, and two other questionnaires measuring health-related quality of 
life. Confirmatory factor analysis was performed to validate the factor structure in the 
Swedish version of the RFIPC and to examine fit of different hypothesized models of 
factor structure. In Study IV, 60 patients were included. They filled in a structured 
diary daily during six months in order to collect information about symptoms and 
potential trigger factors, such as perceived stress. 
Results: No difference could be found in health-related quality of life between patients 
with ulcerative colitis and Crohn’s disease. Scores of health-related quality of life were 
lower for patients with short disease duration than for patients with long disease 
duration. Patients with Crohn’s disease and short disease duration had the lowest 
health-related quality of life. After attending an education programme, an improvement 
was found in the intervention group when measurements were made after one month. 
After six months, no improvement could be shown in health-related quality of life 
when comparing the intervention group with the control group. The RFIPC is the most 
appropriate choice when measuring health-related quality of life, worries and concerns. 
Using the single-factor model (sum score) displayed poor fit indices. The factorial 
structure of the RFIPC, as suggested in the original version, could be replicated with a 
slight modification in the Swedish version and showed the most adequate fit. Perceived 
stress can act as a trigger for relapses in inflammatory bowel diseases. A high level of 
perceived stress was found to have an effect when stratifying level of stress. High level 
of stress one day increased the risk of relapse the next day. 
Conclusion: CD patients with short disease duration have the greatest need of 
education and support. No improvement could be seen in health-related quality of life 
after attending an education programme. The separate factors in RFIPC provide more 
  
detailed information about patients’ disease-related worries and concerns in both 
research and clinical settings. This may help healthcare professionals to provide each 
patient with the appropriate education and support. Identification of trigger factors for 
relapses in inflammatory bowel disease also makes it possible to influence the trigger. 
By extension, this could decrease the number of relapses and improve health-related 
quality of life. 
Keywords: Inflammatory bowel disease, Crohn’s disease, ulcerative colitis, health-
related quality of life, worries, stress 
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1 INTRODUCTION 
 
Patients with inflammatory bowel disease (IBD) have to cope with a lifelong condition 
and make many lifestyle adjustments. Living with IBD and its unpredictable course 
may influence several aspects of life. Worries and concerns related to IBD may affect 
the patient’s adjustment to the illness and compliance with treatment [1, 2]. Patients 
with IBD rate their health-related quality of life (HRQOL) lower than a general 
population [3-6], and disease activity is one of the most important factors for decreased 
HRQOL [3, 5-9]. Therefore, patients with IBD need both treatment for the bowel 
symptoms as well as disease-related information, particularly concerning factors that 
may trigger relapses (especially if the trigger can be influenced). By extension, this 
might lead to fewer relapses, a decrease in patients’ worries and concerns, and also to 
improvements in HRQOL. 
 
I became interested in patients with IBD because of their complex life situation. It is 
not only the disease that needs to be treated; several aspects of life also have to be 
considered. All patients with chronic diseases require information and education to help 
them have a better life in spite of their illness. It is important to support these patients in 
their efforts to cope with the disease, and provide them with as much disease-related 
knowledge as possible. Living with IBD may affect several aspects of life and patients 
have to deal with different lifestyle adjustments. Many questions may arise when 
dealing with for example pregnancies, travelling, symptoms, financial issues and 
different treatments. Availability at the clinic is very important [10]. Patients with IBD 
are often in the middle of life and may find it difficult to keep to fixed telephone hours 
due to their own working- or school hours. In our clinic we changed our way of 
working with IBD patients in 2003, when a clinic especially for IBD patients and 
managed by nurses was started. Availability is one of the most important aspects of the 
clinic. The telephone line is open during the whole day, with an answering machine that 
takes calls when it is not possible to answer. It is the nurses who are in charge of 
patients’ annual visits. Before the IBD clinic was started it was the gastroenterologists 
who took care of these visits, but they could not prioritize the annual visits since they 
had to take care of acute visits and new patients. The nurses also provide patients with 
more structured information, especially those who are newly diagnosed but also those 
who need further knowledge. Today our IBD patients receive both group-based as well 
as individual information, and the aim is to be as available as possible. There is still 
much to learn about IBD. We can learn more from other specialities that work with 
chronic diseases, for example in the area of diabetes, but we also learn a great deal by 
studying our IBD patients. What are their needs and how can we help them to improve 
the way they live and cope with their disease? This thesis tries to clarify a number of 
questions, and by extension this may help nurses and doctors to provide better help for 
IBD patients. 
 
 2 
2 BACKGROUND 
 
2.1 INFLAMMATORY BOWEL DISEASE – IBD 
IBD includes ulcerative colitis (UC) and Crohn’s disease (CD), comprising chronic 
diseases that are characterized by alternating periods of remission and relapses [11, 12]. 
The most common symptoms of UC are diarrhoea, rectal bleeding, and abdominal pain 
[13, 14]. The inflammation is non-transmural and restricted to the colon. The extent of 
the inflammation may vary: proctitis, left-sided colitis (involving the sigmoid colon 
with or without involvement of the descending colon), or fulminant colitis [13]. In CD 
the inflammation is transmural and may affect the entire gastrointestinal tract, from the 
mouth to the anus [13, 15]. The inflammation is often discontinuous (in contrast to UC, 
where the inflammation is always continuous) and complications including strictures, 
abscesses, or fistulas may occur. At diagnosis the disease is located in the terminal 
ileum in 47% of cases, in the colon for 28%, the ileocolon for 21%, and in the upper 
gastrointestinal tract for 3%. The symptoms depend on disease location and may 
include diarrhoea, abdominal pain, fever, clinical signs of bowel obstruction, passage of 
blood or mucos or both [13].  CD and UC are most commonly diagnosed in late 
adolescence and early adulthood but may occur in all ages [16]. Endoscopy with biopsy 
sampling is the gold standard for diagnosing IBD, but blood- and stool samples are also 
necessary [14].  
 
Current IBD medications include corticosteroids, 5-aminosalicylates (5-ASA), 
immunomodulators, biologic agents, and antibiotics [13, 14]. Despite improvements in 
medical treatment, surgery still plays an important role. Indications for surgery include 
bowel perforation, intractable disease despite medical treatment, dysplasia, strictures, 
and fistulas [14].  
 
Patients with IBD have an increased risk of colorectal carcinoma when they have had 
the disease for a long time. Risk factors for colorectal carcinoma are long-term disease 
(more than 8-10 years), young age of onset, extensive colonic involvement, family 
history of colorectal carcinoma, and concomitant inflammatory manifestations, for 
example primary sclerosing cholangitis [17]. The risk is the same in both CD and UC. 
Colonoscopies for screening should begin 8-10 years after the onset of IBD symptoms 
in patients with fulminant UC and patients with CD involving at least one third of the 
colon [17-19]. How often the surveillance colonoscopies should be repeated depends 
on the presence of dysplasia. According to guidelines, the survey should be done every 
1-2 years [17].  
 
2.1.1 Relapses 
The course of UC is characterized by relapses that alternate with periods of remission, 
but for a minority of patients there is a more continuous course. Both the severity of the 
relapses as well as patient response to treatment vary and are difficult to predict [15]. 
For CD patients the course is generally also characterized by alternating periods of 
relapses with remission of varying durations. However, 10-15% of these patients have a 
more chronic, continuous course [15].   
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Both CD and UC seem to become less severe over time. A decrease in symptoms is the 
most common course of the diseases [12, 20, 21]. Five years after diagnosis, the 
majority of UC patients have no symptoms and 40% do not take any medication for 
IBD [20]. Direct costs are highest in the first year after diagnosis and greater in CD 
patients compared with UC patients [21]. A more benign course can be seen in both CD 
patients and UC patients with increasing disease duration [12, 21, 22], but even patients 
with long periods in remission may experience a severe relapse or complication that 
requires surgery. 
 
2.1.2 Aetiology 
The aetiology of IBD is still unknown but it is likely that genetic predisposition, 
environmental factors, and immune dysfunction are all important [23]. The association 
between smoking and IBD is well established. Smokers are at higher risk of developing 
CD than non-smokers, whereas ex-smokers run an increased risk of developing UC 
[15, 24-27]. It has also been suggested that there may be a specific effect of antibiotics 
in early life which may increase the risk of developing IBD, particularly CD, later on 
[24], and possible infectious events may also influence the risk of IBD [27]. A family 
history of IBD is an important risk factor for developing the disease. On average, 8-
10% of CD patients and 6% of UC patients have one or more relatives with IBD [25]. 
  
2.1.3 Incidence and Prevalence 
The highest incidence rates have been reported in northern and western Europe and 
North America [15, 28]. Previous low-incidence areas of eastern Europe, Asia, North 
Africa, and Central and South America have demonstrated a recent increase in the 
incidence and prevalence of IBD [15, 28]. In paediatric IBD, significant increases in 
both incidence and prevalence can be seen [14]. Over the past 50 years the incidence of 
UC has increased and then stabilized, or even decreased, whereas the incidence of CD 
has continually increased [15]. In the United States and Canada there are approximately 
780 000 persons with UC, and 630 000 persons with CD. In Europe, there are 
approximately 2.2 million persons suffering from IBD [16]. 
 
2.2 TRIGGER FACTORS OF RELAPSES 
It is still unknown whether any factors/variables can be triggers of disease relapses. 
However, diet, smoking, infections, antibiotics, and stress have all been reported to be 
potential triggers of relapses in IBD. 
 
2.2.1 Lifestyle Factors  
It has been suggested that specific diet could impact the course of the disease. It is 
possible that an intake of high-fibre, rice-based, and high-fish diets could work as a 
protection against relapse. On the other hand, diets including large amounts of red 
meat, simple sugar, and low fibre could be trigger factors [29]. Studies have shown that 
the course of the disease cannot be influenced by avoiding certain foodstuffs, or by 
adopting a specific diet.  Nevertheless, there is evidence that some diet therapy is 
effective in treating the diseases [30, 31]. Some studies have found that a diet with low 
doses of refined carbohydrate is beneficial for patients, while other studies have been 
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unable to confirm this [30]. Research has shown that an increase in intake of animal 
protein and an increase in intake of omega 6 fatty acid compared with omega 3 fatty 
acid correlated with a high risk of IBD [29].  
 
Patients with UC who smoke are more likely to have a relapse if they quit smoking 
[32], and patients with CD are more likely to be smokers [33]. The properties of 
cigarette smoking that lead to a negative development in CD and protect against disease 
activity in UC are, however, still unknown.  
 
2.2.2 Infection and Antibiotics  
It is suggested that there is a link between systemic or respiratory infection and relapse 
in IBD, but the evidence for this is minimal. It is possible that these infections lead to 
relapses in IBD patients, but it may be that IBD-affected tissues allow for increased cell 
membrane permeability, therefore implying greater potential for pathogenic infection 
[34]. It has also been suggested that enteric infections, for example clostridium difficile, 
cause relapse in IBD, but it is possible that they cause symptoms of their own, rather 
than inducing a relapse [34]. It remains unclear whether the use of antibiotics directly 
triggers a relapse in IBD, and there is as yet no evidence that this should be classified as 
a trigger. The hypothesis is that antibiotics can change beneficial microbial flora, which 
can be injurious in IBD [34].  
 
2.2.3 Stress  
It has been suggested that high stress is associated with relapse in IBD [35-39]. Stress is 
a condition in which person–environment interactions lead to a perceived discrepancy 
between the demands of the situation and the biological, psychological and social 
resources of the person. Stress has been defined as a process in which environmental 
demands tax or exceed the adaptive capacity of an organism, resulting in psychological 
and biological changes that may place persons at risk for disease [40]. Stress can be 
looked at from different perspectives: environmental stress, which includes life events; 
psychological stress, focusing on individuals’ perceived stress; and finally biological 
stress, which focuses on the activation of physiological systems [40].  
 
Some studies have examined the possible association between stress and relapses in 
IBD, and there is some evidence that perceived stress is a trigger [34-37, 39, 41]. 
However, there are studies where no connection could be found [42-44], and other 
studies showing that short-term stress does not trigger relapses but long-term stress 
increases the risk [38]. Others have found an association between stress and relapse in 
UC but not in CD [41]. On the other hand, depressive symptoms seem to have a 
negative effect on the course of CD [45]. 
 
Studies have been made to investigate the effect of stress reduction programmes. Stress 
management psychotherapy does not improve disease activity but improves HRQOL, 
especially in UC patients [46]. So far, the stress reduction programmes that have been 
developed have had little effect on CD patients [45, 46]. 
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Acute psychological stress has several proinflammatory effects at both systemic and 
mucosal levels. For example, stress increases the production of ROM (reactive oxygen 
metabolite), which may contribute to mucosal damage. Stress has also been shown to 
reduce the RMBF (rectal mucosal blood flow), causing mucosal ischaemia which may 
trigger relapses. Increases in both platelet activation and PLA formation (platelet-
leucocyte aggregate) might also be partly responsible for stress-induced symptoms in 
IBD [39].    
 
There are several issues involved in studying the link between stress and relapse in 
IBD. There are, for example, several ways to measure stress. Some studies utilize 
reports of stressful life events. Others use stress diaries or standardized questionnaires, 
while there are also studies that focus on physiological correlates/indices of stress. The 
physiological response to stressful experiences can be studied by measuring urinary 
metabolites of catecholamines or cortisol, making serial measurements of serum or 
salivary cortisol, or by monitoring cardiovascular or immune responses to stress [45]. 
Since a relapse in IBD is a stressful event in itself it may be difficult in cross-sectional 
data to establish whether stress is the cause or the consequence of the relapse. 
 
2.3 HEALTH-RELATED QUALITY OF LIFE (HRQOL)  
Quality of life has been defined as individuals’ perceptions of their position in life in 
the context of the culture and value systems in which they live and in relation to their 
goals, expectations, standards and concerns [47]. HRQOL is the value assigned to 
duration of life as modified by the impairments, functional states, perceptions and 
social opportunities that are influenced by disease, injury, treatment or policy [48]. 
HRQOL is determined by the patient’s physical, psychological and social status, and by 
attitudes, concerns and behaviours in response to the disease [2].  
 
IBD is a disease which has a major impact on patients’ lives. Several studies have 
examined HRQOL in patients with IBD, and it is clear that their HRQOL is impaired 
compared with that of a healthy population [6, 49-55]. Symptom severity is one of the 
most important associations with reduced HRQOL [4-7, 49, 53, 56-60]. In some studies 
it can be demonstrated that CD patients have lower HRQOL compared with UC 
patients [2, 3, 8, 51, 52, 61], but in other studies no differences have been found [6, 54, 
62, 63]. Women are another subgroup for whom HRQOL seems to be reduced [1, 3-5, 
49, 54, 61-64]. So far, few studies have examined the association between HRQOL and 
disease duration. Those that have been conducted have displayed various results. Two 
studies have shown that longer disease duration is associated with better HRQOL [5, 
65], whereas one study did not find any difference between short and long disease 
duration [9].  
 
CD patients in remission, who have low disease activity and no need for medical 
treatment to maintain remission, have 3.5 times lower costs (both direct medical costs 
and costs for lost productivity) than patients with a more active disease. Also, patients 
that respond to treatment have lower costs and better HRQOL compared with patients 
where disease activity is high but no treatment is given or there is no response to 
treatment [66] .  
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There seems to be a complex relationship between biopsychosocial factors and 
HRQOL. Different aspects of well-being interact with various biopsychosocial factors 
in determining the IBD patient’s well-being [67]. Psychological factors, such as 
depressive mood associated with anxiety and poor HRQOL, seem to have a negative 
influence on the course of IBD [68].  
 
2.4 WORRIES AND CONCERNS 
Everyone worries from time to time, even those who do not suffer from a chronic 
disease. Worry involves a predominance of negative verbal thoughts. We talk to 
ourselves about negative things and what may happen in the future [69]. The highest 
rated reasons for worrying are that it helps to discover ways of avoiding negative future 
events and it prepares us for the worst scenario if this cannot be avoided [70]. Most 
people with a chronic disease have many worries and concerns. Even if they do not 
have any symptoms they may feel worried since they do not know how they are going 
to feel tomorrow. High levels of worry are associated with increased threat and 
negative content in cognitive representations of illness [71]. Worry predicts anxious 
and depressive symptoms and correlates positively with a disengagement of coping 
efforts, and negatively with perceived coping effectiveness [72]. 
 
Among the many worries and concerns of IBD patients in relation to the disease, the 
most important are related to surgery, energy level, having an ostomy bag, the uncertain 
nature of the disease, the effects of medication, being a burden on others, loss of bowel 
control, developing cancer, the ability to achieve full potential, pain or suffering [1, 2, 
63, 64, 73]. The illness may lead to several consequences in the person’s life affecting 
work, education, family life, sexual life and social relationships. Making adjustments 
becomes part of everyday life. The patient’s worries and concerns may also decrease 
HRQOL and affect the clinical outcome.  
 
Some young people with CD describe life as a roller coaster of fears and hopes, the 
known and the unknown. They experience extreme exhaustion, debilitating surgery, 
and near-death experiences as they seesaw between wellness and illness, and hope for a 
better future [74]. Many patients with IBD spend considerable time thinking and 
worrying, and planning around the disease [75]. Some patients have described that even 
in remission they find it difficult to feel secure because the habit of being ill is so 
strong. It can take them several months of remission before they feel confident enough 
to participate in different activities [10].  
 
2.5 DEPRESSION AND ANXIETY 
There is a higher rate of depression and anxiety in IBD patients than in the general 
population [76]. There also seem to be more severe depressive and anxiety symptoms 
when the IBD is active [8, 76]. Patients with CD have more anxiety and depression 
compared with UC patients [8, 53].  
 
Patients with IBD may have great psychosocial restrictions due to their disease and 
express a greater need for psychological interventions than patients with rheumatoid 
arthritis. The psychological factors are mainly worries about the impact of the disease 
and anxiety [77].   
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2.6 COPING  
People with chronic diseases may have major limitations in physical, emotional, social 
and occupational functioning. It has been shown that psychological factors, in 
particular cognitive representations, coping efforts, and appraisals of coping efforts, 
play a crucial role in adaptation to a chronic disease. Coping behaviours are influenced 
by the person’s representation of the illness and appraisals of coping efforts. Coping 
efforts aim to avoid or reduce the negative consequences of the illness [78].  Coping 
has been defined as constantly changing cognitive and behavioural efforts to manage 
specific external and/or internal demands that are appraised as taxing or exceeding the 
resources of a person [79]. The threat of illness may produce an emotional response. 
This emotion might increase or decrease the intensity of illness symptoms and generate 
symptoms that could be confused with those of the illness. This could lead a person to 
concentrate on the most negative consequences of the illness [80]. 
 
Coping is a process that changes over time and across situations. During the process of  
coping, the situation itself or the person’s feelings about it change; this requires new 
appraisals, which in turn leads to new coping strategies [79] 
 
In patients with IBD, the most frequently used coping strategies are characterized by 
optimism, self-reliance, confrontation, acceptance, and seeking emotional support [8, 
81]. IBD patients often wished that the problem would go away, tried to keep the 
situation under control, or hoped that things would get better [8, 82]. Many patients 
also tried to think positively and tried to keep their feelings under control [8].  
 
Less effective coping strategies such as substance use, expressing anger, self-distraction 
and self-blame are associated with higher disability, psychological distress and poorer 
physical and mental health [81]. Depressive coping is characterized by social 
withdrawal, irritable behaviour towards others, self-pity, and pessimistic thinking. 
Depressive coping is dysfunctional with regard to emotional and physical well-being 
and is strongly and negatively associated with reduced HRQOL [60, 63]. 
 
2.7 COMPLIANCE AND ADHERENCE  
Non-adherence and non-compliance is common in IBD and may result in more 
relapses. Those who are most non-adherent are young patients, when they are in 
remission and taking maintenance therapies for IBD [83]. This may result in an overuse 
of health resources with a shift from cost-effective preventive care to more emergency 
treatment of relapses. It may also lead to financial loss due to the patients’ inability to 
work, or that family members have to take time off work to take care of patients [84]. 
Shared decision-making between patients and physicians appears to be more powerful 
when it comes to encouraging the patient regarding adherence and compliance [83-85]. 
Patient education is another way to deal with this [83, 84].  
 
2.8 INFORMATION AND EDUCATION  
Perceived level of IBD information correlates with patients’ concerns. Lower scores for 
the level of information are associated with more concerns [73]. Patient education can 
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lead to more effective coping strategies, less anxiety and depression, and reduced IBD 
symptoms [86]. IBD patients call for information about their disease and how to 
manage it, but they want more than they are given [87, 88].  
 
How should IBD patients be educated about their disease? Among the different ways 
that have been tested, group-based education programmes have been very much 
appreciated by patients, and knowledge scores have been improved. These programmes 
include between four and nine sessions, of around two to three hours per session, 
covering various topics, which are most often presented by gastroenterologists, 
dieticians, surgeons, psychologists, social workers, and nurses. The groups contain 
about 8-12 patients and in some education programmes family members are welcome 
[86, 89-91].  
 
It is important to give disease-related information to newly diagnosed patients. These 
patients often need several clinical visits at the beginning of their disease to ensure that 
all important issues are covered [84, 92].  
 
Self-management is a way to teach patients with a chronic disease to be more involved 
in their own care. This has been tested in the form of a patient guidebook, which 
contains information about investigation and treatment. It also contains self-
management of IBD and indicated areas where patient choice might influence treatment 
decisions. Guided self-management is a written plan to which patients can refer when 
making decisions about treatment and the need for service contact [93]. They need to 
work in partnership with their doctors, and this can be achieved by using patient-
centred consultants. The gastroenterologists or specialist nurses should however be 
trained in patient-centred communication for the self-management to be as effective as 
possible [94].  
 
Many patients with IBD are young and eager to learn more about their disease. A 
considerable amount of medical information is readily accessible on the Internet and it 
is quite common that newly diagnosed IBD patients are already well informed on their 
first visit to the clinic. Gastroenterologists and specialist nurses need to learn more 
about the information that is available on the Internet in order to help the patients find 
and use appropriate websites [84]. 
 
Knowledge about the disease and how to manage it is essential for patients with a 
chronic disease such as IBD. This may have a positive influence on HRQOL and the 
capacity to handle treatment. 
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3 RATIONALE 
 
The incidence of IBD has increased. Due to the increasing number of patients and the 
fact that the number of healthcare professionals is not increasing, it is becoming 
essential to learn more about HRQOL. Which patients have the greatest need for 
education and support?  It has been shown in the literature that patients with IBD have 
poor HRQOL compared with a healthy population. They also have a number of worries 
and concerns. IBD patients need and call for disease-related information, but there are 
still some questions remaining about how this information should be provided in order 
to increase HRQOL. It is also important to gain more knowledge about the issues that 
are most burdensome for IBD patients. This helps to individualize patient education 
and support. Healthcare professionals can then focus on these topics, with the aim of 
reducing patients’ IBD symptoms and stress, and promoting effective coping strategies. 
In the long run this could lead to fewer worries, improved HRQOL, and fewer relapses.  
 
Several studies have shown that disease activity is the most important factor for 
reduced HRQOL. It is therefore fundamental to gain more information about what may 
trigger relapses in IBD, especially if the trigger can be influenced. In this way patients 
can be better informed and better supported in this area, which could lead to fewer 
relapses and increased HRQOL. 
 
It is extremely important to have a deeper insight into HRQOL and the worries and 
concerns of IBD patients, in order to better understand them. In this way we can 
develop more effective nursing intervention programmes, providing the best possible 
education and support. It is essential to have the right measurements in order to identify 
which patients have the greatest need of education and support, and to identify which 
issues patients are most worried about. For further studies in this area it is also 
important to find a good tool for measuring trigger factors for relapses. All this may 
influence the clinical course for the patients. 
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4 AIMS OF THE THESIS 
 
4.1 GENERAL AIM 
The general aim of this thesis was to gain scientific evidence about worries and 
concerns, HRQOL, and trigger factors for relapses, and to develop and evaluate an 
education programme. 
 
4.2 SPECIFIC AIMS 
The specific aims for each study were: 
• To create an education programme which would be suitable for patients with 
newly diagnosed IBD and which could be readily applied at the clinic, and to 
investigate whether a group-based education programme could improve 
HRQOL among patients with IBD (Study I). 
• To identify predictors of low HRQOL among patients with IBD and make a 
comparison between CD and UC with respect to disease duration (Study II). 
• To validate the factor structure in the Swedish version of the RFIPC and to 
explore how these hypothesized different factors are associated with HRQOL 
and general health (Study III). 
• To examine whether perceived stress has a short-term acute effect, i.e. whether 
it acts as a trigger, for the risk of relapse in IBD (Study IV). 
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5 METHODS 
 
Table 1. Overview of Studies I-IV 
 Study I Study II Study III Study IV 
Design Randomized 
controlled trial 
Cross sectional 
study 
Methological 
study 
Case-crossover 
study 
Inclusion 
criteria 
CD or UC 
<2 years duration 
Clinical remission 
No other chronic 
disease 
Swedish language 
 
CD or UC 
< 2 years or > 5 
years of duration 
Clinical remission 
No other chronic 
disease 
Swedish language 
 
CD or UC 
Clinical remission 
No other chronic 
disease 
Swedish language 
 
CD or UC 
< 2 years of 
duration 
Clinical remission 
No other chronic 
disease 
Swedish language 
No surgery due to 
IBD 
 
Participants N=93 N=197 N=195  N=60  
Main  
outcome 
Education, 
HRQOL 
HRQOL Worries and 
concern 
Stress 
 
 
5.1 INSTRUMENTS  
A combination of generic and disease-specific questionnaires was used in Studies I and 
II, to describe and measure HRQOL and worries and concerns in patients with IBD. In 
Study III, the same combination was used but in order to validate one of the disease-
specific questionnaires. In Study IV, a structured diary was used.  
 
Table 2. Overview of instruments used in Studies I-IV 
Instruments Study I Study II Study III Study IV 
The Health Index x x x  
The SOC x x   
The IBDQ x x x  
The RFIPC x x x  
Evaluation of education x    
The Diary    x 
HBI  x x x 
UC-DAI  x x x 
Truelove & Witts Index    x 
 
 
5.1.1 The Health Index  
The Health Index (HI), used in Studies I, II, and III, is a generic questionnaire. It 
contains nine questions describing the patient’s general health [95], and includes 
questions regarding energy, temper, fatigue, loneliness, sleep, vertigo, bowel function, 
pain and mobility. Each question is graded: 1=very poor, 2=rather poor, 3=rather good, 
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4=very good. The total score ranges from 9 (very poor general health) to 36 (very good 
general health). The internal consistency reliability measured with Cronbach’s alpha 
coefficient reached acceptable levels in all studies using the HI. 
 
5.1.2 The Sense of Coherence Scale  
The short form of the Sense of Coherence (SOC) questionnaire, used in Studies I and 
II, is a generic instrument that measures coping capacity [96]. The concept of SOC 
includes three components: the perception of comprehensibility, manageability, and 
meaningfulness. The questionnaire contains 13 questions, each with a scale graded 
from 1 to 7. Possible scores range from 13 to 91. A high score indicates a strong sense 
of coherence. With a strong sense of coherence, it is more likely that a person will cope 
successfully with stressful situations. The rationale for using this questionnaire is based 
on an increased interest in the phenomenon of coping related to stress, and the way in 
which this is related to illness and health. The SOC questionnaire has been shown to 
have adequate reliability and validity in Sweden [97, 98]. The internal consistency 
reliability measured with Cronbach’s alpha coefficient reached acceptable levels in all 
studies using the SOC. 
 
5.1.3 The Inflammatory Bowel Disease Questionnaire  
The Inflammatory Bowel Disease Questionnaire (IBDQ), used in Studies I, II, and III, 
is a disease-specific questionnaire used for assessing HRQOL in patients with IBD. It 
has 32 items, divided into four subscales: bowel symptoms (bowel movements and 
abdominal pain), systemic symptoms (fatigue and sleep), emotional function (irritation, 
depression and aggression), and social function (ability to work and participate in social 
activities). The IBDQ has been shown to be a reliable and sensitive measure of 
HRQOL [99, 100] and it has been validated in Sweden [101, 102]. In Studies I, II, and 
III, we used the response option that is used in the UK version of the IBDQ, since it is 
more differentiated [103]. In this version, a 4-graded Lickert scale is used instead of the 
7-graded Lickert scale that was developed by Guyatt et al. [99]. Score 1 represents the 
“best function” and score 4 represents the “worst function”. We used all 32 items [99] 
and the total score ranges from 32 (optimal HRQOL) to 128 (worst HRQOL). The 
modified version of the IBDQ was tested for reliability and validity in Study I by using 
Cronbach’s alpha coefficient and Rasch analysis [104]. The internal consistency 
reliability measured with Cronbach’s alpha coefficient reached acceptable levels in all 
studies using the IBDQ. 
 
5.1.4 The Rating Form of Inflammatory Bowel Disease Patient 
Concerns  
The Rating Form of Inflammatory Bowel Disease Patient Concerns (RFIPC), used in 
Studies I, II, and III, is a disease-specific questionnaire that rates important worries and 
concerns of patients with IBD. The RFIPC contains 25 items or concerns that are 
graded on 100 mm visual analogue scales, where the extremes are 0 mm=”not at all”, 
and 100 mm=”a great deal”. The basic formulation is “Because of your condition, how 
concerned are you about…?” The items or concerns are for example “having surgery”, 
“feeling alone”, “uncertain nature of the disease”, “effects on medication”, “being a 
burden on others”, “loss of sexual drive”. It has been shown that the RFIPC is a reliable 
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and sensitive measure of the worries and concerns expressed by patients with IBD, for 
use in clinical care and in research [1]. In the original version of the RFIPC, the 25 
items are divided into four factors: impact of the disease, sexual intimacy, 
complications of the disease and body stigma. In Sweden it is mostly the sum score (the 
mean of the 25 items) that is reported in the studies using the questionnaire. In Studies I 
and II, we reported the results of the RFIPC by displaying the sum score. In Study III, 
we validated the factor structure. The internal consistency reliability measured with 
Cronbach’s alpha coefficient reached acceptable levels in all studies using the RFIPC. 
 
5.1.5 Evaluation of the Education Programme 
The patients in the intervention group in Study I filled in a questionnaire for evaluation 
of the group-based education programme. The patients were asked about the point of 
time for the sessions, how the group was composed and how satisfied they were with 
the education programme. Response alternatives were graded from 1 to 7, where 1 was 
the worst score and 7 the best possible score. The patients were also asked about their 
general opinion of the education programme. 
 
5.1.6 The Diary 
To collect information regarding symptoms of IBD and a number of potential triggers, 
a diary was constructed for Study IV. The potential triggers included were based on 
previous literature reported on possible triggers for relapse [34, 105]. Questions in the 
diary were used to identify relapses and concerned number of loose stools during 
daytime and night-time, occurrence of urgency, blood in stools, and abdominal pain, 
with a scale graded from 0 to 4 (0 = no problem to 4 = all the time). One question 
concerned the patients’ general well-being, with a response scale graded from 0 to 4 (0 
= very good to 4 = very bad). Perceived stress was measured with the question “Have 
you felt stressed today?” and a five-graded response scale ranging from 0 to 4 (0 = not 
at all to 4 = a lot). Another question concerned changes in food intake regarding sugar, 
fat, and fibre graded on a three-point scale. A further question dealt with smoking; 0 = 
no (non-smoker) and 1 = yes (smoker), and if “yes” the patients had to state the number 
of cigarettes per day. The non-smokers were asked if they had stopped smoking and if 
so, when. The last question dealt with having an infection, for example a cold or an 
enteric infection, and whether they had taken antibiotics, with two response 
alternatives, 0 = no and 1 = yes. In the diary it was also possible for patients to state if 
their medical treatment had been changed, and to give information about additional 
trigger factors such as divergences from their normal life situations.  
 
Patients were instructed to fill in the diary every day during 26 weeks. 
 
5.1.7 The Truelove and Witts Index 
The Truelove and Witts Index is commonly used to assess disease severity. The 
severity of the illness is assessed according to severe, moderate, and mild. Severe 
disease is when the patient has diarrhoea six or more times a day with macroscopic 
blood in the stools, fever, tachycardia, and anaemia. Mild disease is when the patient 
has mild diarrhoea (maximum four times per day) with no more than a small amount of 
macroscopic blood in the stools, no fever, no tachycardia, and no severe anaemia. 
Moderate disease is between severe and mild [106]. In Study IV, the Truelove and 
Witts Index was used to identify relapses. 
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5.1.8 The Harvey-Bradshaw Index 
The Harvey-Bradshaw Index (HBI) was developed to assess the degree of illness in 
patients with CD. The criteria included are: number of liquid or soft stools per day, 
abdominal pain rating (0-3), general well-being rating (0-4), presence of abdominal 
mass (0=none, 1=dubious, 2=definite, 3=definite and tender), complications: arthralgia, 
uveitis, erythema nodosum, pyoderma gangrenosum, anal fissure, new fistula, abscess 
(score 1 per item). An HBI score of less than five is defined as being in remission, 5 to 
7 as mildly active disease, 8 to 16 as moderately active disease, and >16 as severely 
active disease [107, 108]. The HBI was used in Studies II, III, and IV to assess whether 
the patients were in remission before inclusion. 
 
5.1.9 The Ulcerative Colitis Disease Activity Index 
The Ulcerative Colitis Disease Activity Index (UC-DAI) is used to measure degree of 
illness in UC. The UC-DAI is the sum of scores from four criteria: stool frequency, 
rectal bleeding, mucosal appearance, investigator’s rating of disease activity. Each of 
the criteria can be ranked from 0-3. UC in remission is defined as two or fewer points. 
Severe disease is defined as greater than nine points [109]. The UC-DAI was used in 
Studies II, III, and IV to determine if patients were in remission before they were 
included.  
 
5.2 PARTICIPANTS AND PROCEDURE 
In Studies I, II, and III, missing values are accounted for by using the mean substitution 
procedure. The missing values for a variable are replaced by a mean value of that 
variable, calculated from all valid responses [110]. 
 
5.2.1 Study I 
 
Figure1. Overview of participants and dropouts in Study I 
 Intervention group 
n=55 Baseline  
 Included  
n=99
Control group 
n=44
Control group 
n=38
6 months  Intervention group 
n=52 
Control group 
n=32
Fulfilled the inclusion 
criteria n=116
Dropped out 
n=6 
Education programme 
1 month  
Dropped out 
n=3 Dropped out 
n=6 
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Participants 
Patients suffering from CD or UC for less than two years, who were in clinical 
remission and visited the IBD clinic at Danderyd Hospital between November 2002 
and November 2004, were invited to participate in the study. To be included, they were 
to suffer from no other chronic diseases, have a good understanding of the Swedish 
language and be able to fill in a questionnaire. Clinical remission was defined as having 
no bowel symptoms associated with active disease, i.e. no diarrhoea or blood in the 
stools, and undergoing no acute treatment. A total of 116 patients fulfilled the inclusion 
criteria and were invited to participate in the study. Ninety-nine patients (85%) gave 
their informed consent. Fifty-five patients were randomized to the intervention group 
and 44 patients were randomized to the control group. Six patients in the control group 
dropped out when they were informed that they had not been randomized to the 
intervention group. The control group therefore remained at 38 patients. 
 
Procedure 
The 116 patients who fulfilled the inclusion criteria were sent a letter enclosing written 
information about the study, and the questionnaires. Randomization was performed by 
using blocks of 20 patients: 10 were allocated to either an intervention group or a 
control group. Both groups completed the questionnaires at baseline and after six 
months. The intervention group also completed the questionnaires after the group-based 
education programme, one month after baseline. 
 
Three patients in the intervention group and six patients in the control group did not 
return the questionnaires at the six-month measurement. After two reminders they were 
excluded from the study. The analyses are therefore restricted to “per protocol” 
analyses. 
 
When the patients were included in the study they were in clinical remission. The 
patients’ files were scrutinized to identify illness activity during the six-month study 
period. 
 
The multi-professional group-based education programme 
The content of the multi-professional, group-based education programme was first 
tested in a pilot study including eleven participants. The result showed that the content 
was well suited for patients with IBD with the exception of the number of sessions. 
Many of the patients had difficulty finding time to participate in an education 
programme. Therefore, after the evaluation, the number of sessions was reduced from 
four to three. The intervention group was divided into groups of eight to ten patients, 
and each patient was invited to bring a significant other of his/her own choice. The 
patients with CD and the patients with UC were divided into separate groups. The 
education programme was held once a week and consisted of three two-hour sessions. 
It was scheduled in the evening for the convenience of the patients. A specialist nurse, 
gastroenterologist, dietician and a medical social worker gave the lectures. The 
specialist nurse worked as a coordinator and attended every meeting. The content was 
based on clinical experience, literature studies and contacts with other 
gastroenterological clinics with experience of similar education programmes. The 
topics for the sessions were aetiology and nature of the diseases, examinations, 
treatments, side effects, new research, nutrition, financial issues, psychological 
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reactions, coping, behavioural changes, information concerning the organization and 
care of IBD patients at the clinic, and demonstration of a sigmoideoscope. During every 
session there was time to ask questions and to discuss personal experiences. At the last 
session, the patients received a written summary of the contents of the education 
programme. 
 
5.2.2 Study II 
Figure 2. Overview of participants in Study II 
 
Participants 
Patients with CD or UC who were in clinical remission and receiving care at the IBD 
clinic at Danderyd Hospital were invited to participate in the study. To be included, 
they were to suffer from have no other chronic diseases, have a good understanding of 
the Swedish language and be able to fill in a questionnaire. They were to have had the 
disease for less than two years (short-duration group) or more than five years (long-
duration group). Clinical remission was defined as having no bowel symptoms 
associated with active disease, i.e. no diarrhoea, no blood in stools and no acute 
treatment. Furthermore, UC patients were to have an UC-DAI score of 2 or less [109], 
and CD patients were to have a HBIc score of less than 5 [107, 108]. A total of 319 
patients matched the inclusion criteria and were invited to participate in the study. A 
total of 197 patients (61%) gave their informed consent and were included. The study 
population was then divided into a CD group and an UC group. Each group was also 
divided into separate groups based on short disease duration (less than two years) or 
long disease duration (more than five years). In the CD group there were 44 patients 
with short disease duration and 39 patients with long disease duration. In the UC group 
there were 40 patients with short disease duration and 74 patients with long disease 
duration.  
 
 Fulfilled the inclusion 
criteria n=319
Included 
n=197
CD 
Short-duration 
group 
n=44 
CD 
Long-duration 
group 
n=39 
UC 
Short-duration 
group 
n=40 
UC 
Long-duration 
group 
n=74 
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Procedure 
A letter with information about the study and the four questionnaires was sent to the 
319 patients that fulfilled the inclusion criteria. One reminder was sent to non-
responders after six weeks. The questionnaires were completed on one occasion. 
 
5.2.3 Study III 
Participants 
A total of 195 patients with CD and UC who were receiving care at the IBD clinic at 
Danderyd Hospital were included in the study. They were to be in clinical remission, 
suffer from no other chronic diseases, have a good understanding of the Swedish 
language, and be able to fill in a questionnaire. Clinical remission was defined as 
having no bowel symptoms associated with active disease, i.e. no diarrhoea, no blood 
in stools and no acute treatment. Furthermore, UC patients were to have an UC-DAI 
score of 2 or less, and CD patients were to have an HBI score of less than 5. 
 
Procedure 
The patients were sent a letter including information about the study, the RFIPC, the 
IBDQ and the HI. The patients filled in the questionnaires on one occasion. 
 
5.2.4 Study IV 
Figure 3. Overview of participants in Study IV 
 
Participants 
A nurse specially trained in IBD, identified the patients from a local register at the IBD 
clinic at Danderyd Hospital. Those who were eligible for participation were patients 
with CD or UC, who had suffered from the disease for less than two years, had no other 
chronic diseases, had not undergone surgery due to their IBD, and were in clinical 
remission.  Clinical remission was defined as having no bowel symptoms associated 
with active disease, i.e. no diarrhoea, no blood in stools and no acute treatment. 
Furthermore, UC patients were to have an UC-DAI score of 2 or less, and CD patients 
were to have an HBI score of less than 5. A total of 113 non-consecutive patients were 
invited to participate, and 60 (53%) accepted and were included. Of these 60 patients, 
50 (84%) participated throughout the whole study. The ten patients who discontinued 
stated reasons such as low motivation or forgetting to fill in the diary, or they 
experienced that it was not meaningful since there was no variation in the reported 
variables. 
 Fulfilled the inclusion 
criteria n=113
Included 
n=60 
Completed 26 weeks 
n=50
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Procedure 
After identification, the patients were sent a letter including information about the 
study. Those who gave informed consent were then given detailed information by 
telephone. After being included, the patients were instructed to fill in a diary every day 
during a 26-week period. They were asked to send in completed diary pages every 
fourth week. If the pages were not sent in, a reminder was sent after four weeks.  
 
A pre-test study was conducted before the main study. Two patients tested the designed 
diary by filling it in every day for one month. After the pre-test study the diary was 
slightly adjusted. For example, an open question was added to give the participants the 
opportunity to provide other subjective information. 
 
Relapse of IBD was defined in the diary according to Trulove and Witt criteria [106], 
i.e. blood in stools for patients with UC and for patients with CD in the colon. For 
patients with CD in the small bowel, relapse was defined as more than two consecutive 
days of abdominal pain. Identified relapses in the diary were checked by scrutinizing 
the medical files. 
 
Onset of a relapse was considered as the first day with a relapse. A relapse was 
considered as over when 14 consecutive days had passed with no blood in stools, no 
diarrhoea, or no abdominal pain. 
 
The case-crossover design was used. This is an epidemiological design developed to 
study triggers for acute events, and constitutes a valuable methodology for establishing 
causality between stress and relapses in IBD [111]. The method departs from the 
assumption that if there are factors influencing the onset of an outcome, in this case a 
relapse in IBD, these would more often be present during a period just before the onset 
than during periods further from the onset [112]. Only cases were examined and were 
self-matched by serving as their own controls. 
 
5.3 DATA ANALYSIS 
Table 3. Overview of statistical analysis used in Studies I-IV 
Statistical analysis Study I Study II Study III Study IV 
Student’s t-test x x   
Chi-squared test x x   
ANOVA x    
Mann-Whitney U-test x  x  
Spearman’s correlation x  x  
Pearson’s correlation  x   
Second-order factor analysis  x   
MANCOVA  x   
CFA   x  
Cronbach’s alpha   x  
Matched-pair interval    x 
Usual frequency    x 
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Student’s t-test and the chi-squared test were performed to compare demographic 
background data between the intervention group and the control group (Study I), and 
between the short-duration groups and the long-duration groups (Study II).  
Cronbach’s alpha coefficients were calculated for the instruments HI (Studies I, II, III), 
SOC (Studies I, II), the IBDQ (Studies I, II, III), and the RFIPC (Studies I, II, III) to 
provide measures of internal consistency. 
 
5.3.1 Analysis Study I 
In order to compare the intervention group with the control group at baseline and at six 
months, and for comparisons in the intervention group at baseline, one month, and six 
months, analysis of variance (ANOVA) with repeated measures was performed. The 
Mann-Whitney U-test was used for more detailed analysis of the changes over time. 
Correlation between variables was calculated using Spearman’s rank correlation.  
 
5.3.2 Analysis Study II 
Correlation between variables was calculated by using Pearson’s correlation 
coefficient. Significant correlations were displayed for both CD patients and UC 
patients between the HI, the IBDQ and the RFIPC. A 2 x 2 multivariate analysis of 
covariance (MANCOVA) with SOC and natural log-transformed number of relapses as 
covariates was performed to examine the impact of diagnosis and disease duration.  
 
5.3.3 Analysis Study III 
Confirmatory factor analysis (CFA) was performed on the variance-covariance matrix 
of the RFIPC items to assess the fit of the factorial structure of the RFIPC to the data. 
Cronbach’s alpha coefficient was calculated to test reliability. In order to follow up the 
results from the CFA, Spearman’s correlation analysis and the Mann-Whitney U-test 
were performed.  
 
5.3.4 Analysis Study IV 
Exposure frequency during the period just before onset of a relapse (the case period) 
was compared with exposure frequency during one or several control periods during 
remission. The matched-pair interval approach and the usual frequency approach were 
performed. The matched-pair interval approach uses exposure status during a matched 
time period, e.g. the same weekday as the day before the onset of a relapse, but a week 
earlier. The usual frequency approach was based on the frequency of exposed days 
during the control period. The 1-7 days prior to the onset of a relapse were considered 
as the case period and the 8-14 days prior to the onset of a relapse were considered as 
the control period. Hazard periods of varying length were tested.  
 
Conditional logistic regression was used in the matched-pair interval approach for 
estimation of odds ratio (OR) and 95% confidence intervals. Standard Mantel-Haenzel 
estimates for sparse data were used for analysis in the usual frequency approach for 
estimation of OR and 95% confidence intervals.  
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6 ETHICAL CONSIDERATIONS 
 
The four studies were all approved by the local Ethics Committee, Karolinska Institutet 
(Dnr. 01-224, 04-813T). 
 
In all four studies, the patients received written information about the study. The 
information included the aim of the study and assurance of confidentiality. The patients 
were also informed that participation was voluntary and that they could withdraw from 
the study at any time. The patients were asked to give their informed consent if they 
wanted to participate in the study.  
 
All data were handled anonymously. The questionnaires used in Studies I, II, III and 
the diary in Study IV were provided with a patient code to ensure confidentiality. The 
patient codes and the information about the patients’ names are stored in two different 
locked safes.  
 
In Study I, the patients in the control group were invited to participate in the education 
programme after completion of the questionnaires at the six-month measurement. 
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7 RESULTS 
 
7.1 HRQOL AND PATIENT EDUCATION (STUDY I) 
There were no differences between the intervention group and the control group 
regarding demographic and disease-related factors. 
 
A significant difference was found when comparing the RFIPC at baseline and one 
month later, showing that patients had lower RFIPC scores immediately after the 
education programme. When comparing with the control group, no improvement could 
be seen in HRQOL in patients with IBD at the six-month follow-up. The education 
programme was highly appreciated by the patients. 
 
A significant correlation was found for all patients between the HI and the IBDQ, and 
the HI and the RFIPC, in the measurements at baseline and at six months, indicating 
that the higher the perceived general health, the better the perceived HRQOL. There 
were no differences in gender for any of the measurements. 
 
7.2 PREDICTORS OF LOW HRQOL (STUDY II) 
There were no differences between the groups regarding demographic and disease-
related factors, except for patients in the long-duration groups who had a significantly 
larger number of relapses compared with patients in the short-duration groups. 
 
Disease duration had a significant effect on HRQOL; scores of HRQOL were lower for 
patients with short disease duration than for patients with long disease duration. There 
were no significant differences in HRQOL between patients diagnosed with CD and 
UC. The analysis showed a significant interaction between diagnosis and disease 
duration with regard to HI and the IBDQ. The analysis displayed significantly lower 
scores on the HI (low HRQOL) and higher scores on the IBDQ (low HRQOL) for CD 
patients with short disease duration than the other groups. 
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Figure 4. The Health Index and the IBDQ as dependent variables in a MANCOVA 
with Sense of Coherence and log-transformed number of relapses as covariates, and 
disease duration and Diagnosis x Disease duration as independent variables with 
significant effects. Estimated means in the figure are presented as z-scores at Sense of 
Coherence Z=0.08, and log-transformed number of relapses Z=0.90. 
 
7.3 WORRIES AND CONCERNS (STUDY III) 
Three models of the RFIPC were tested. The first model to be validated was the single-
factor model of the RFIPC, which is based on the assumption that the variance in the 
questionnaire could be placed in one single factor of worry. The one-single factor 
model is the most commonly used scoring procedure in Sweden. The second model 
was the four-factor model according to Drossman et al. [1], in which the RFIPC 
consists of four distinct factors: impact of disease, sexual intimacy, complications, and 
body stigma. The third and final model was the four-factor model with the addition of 
correlated error terms between item 5 (developing cancer) and item 6 (dying early), and 
item 16 (having surgery) and item 17 (having an ostomy bag). Inclusion of correlated 
error terms for subgroups of items is generally not recommended. However, it was 
considered to be appropriate in this analysis due to clinical observations. An ostomy 
bag is often the consequence of having surgery, and the fear of dying early is normally 
related to concerns about developing cancer. 
 
The analysis showed that the single-factor model had poor fit indices. The four-factor 
model displayed better fit compared with the single-factor model, but failed to 
approximate the established thresholds for the fit indices. The four-factor model 
permitted correlated error terms between items 5 and 6, and items 16 and 17 displayed 
the most adequate fit. All Cronbach’s alpha coefficients for the factors in the final 
model were acceptable (all alphas >0.88). 
 
Significant correlations were found between the four factors of the RFIPC and the four 
factors of the IBDQ and the HI. The correlation between the four factors of the RFIPC 
and emotional function (the IBDQ) showed the highest correlation coefficients, while 
correlation coefficients regarding systemic symptoms showed the lowest correlations. 
Greater worries and concerns regarding impact of disease were reported by CD patients 
than by UC patients (statistically significant). 
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Figure 5. Graphical representation of the correlated four-factor model of the RFIPC. 
The factor loadings are standardized loadings.  
 
7.4 STRESS AS A TRIGGER FACTOR (STUDY IV)  
Twenty-five patients experienced one or several relapses during the data collection, and 
a total of 42 relapses were identified. Of the potential trigger factors included in the 
diary it was only perceived stress that displayed an effect. In 19 of the 42 relapses the 
patients were exposed to stress on the day before the onset of a relapse. Stress on one 
day increased the risk of relapse on the next day with an OR of 2.48 (95% CI 1.07-
5.78) for the usual frequency, and 2.67 (95% CI 0.71-10.05) for the matched-pair 
interval analyses. No increased effect estimates were found for hazard periods further 
than one day from onset. 
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When stratifying level of stress, the analysis showed an effect for high levels of 
perceived stress. When reporting “quite a lot” of stress, an OR of 4.8 (95% CI 1.09-
21.10) was found. No statistically increased risk for lower levels of perceived stress 
was displayed, although elevated effect estimates were found for “some” stress. No one 
reported having “a lot” of stress during the day before onset of a relapse. Stratification 
of the analysis with respect to diagnosis gave an OR of 7.33 (95% CI 0.94-57.33) for 
CD patients, and 1.88 (95% CI 0.94-4.87) for UC patients. 
 
If the analysis was restricted to the first relapse during follow-up, this did not change 
the results.  
 
Table 4. Odds ratio (OR) for relapse in IBD after exposure to stress during the previous day, 95% 
confidence interval (95% CI) 
 
Analytical approach Level of stress 
 1 2 3 4 
 Odds 
ratio 
95% 
confidence 
interval 
Odds 
ratio 
95% 
confidence 
interval 
Odds 
ratio 
95% 
confidence 
interval 
 
Usual frequency 
(95% CI) 
1.38 
 
(0.60-3.16) 2.57 
 
(0.55-11.93) 4.8 
 
(1.09-21.10) - 
Matched-pair 
interval 
1.00  
 
(0.32-3.10) 3.00 
 
(0.31-28.84) 4.00 
 
(0.45-35.79) - 
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8 DISCUSSION 
 
The general aim of this thesis was to gain scientific evidence about worries and 
concerns, HRQOL, and trigger factors for relapses, and to develop and evaluate an 
education programme. In Studies II and III, newly diagnosed CD patients were found to 
have the lowest HRQOL, and a questionnaire for measuring worries and concerns was 
validated. In Study IV, perceived stress was identified as an important factor in 
triggering relapses in IBD. In Study I, a group-based education programme was 
developed and evaluated. The education programme was highly appreciated by the 
patients but no improvements in HRQOL could be found.  
 
In the following sections, the discussion will focus on each topic in this thesis. 
 
8.1 HRQOL AND PATIENT EDUCATION 
The multi-professional group-based education programme was highly appreciated by 
the patients. An improvement in HRQOL could be seen in the intervention group 
immediately after the education programme. However, no improvement in HRQOL 
could be found six months after attending the education programme when comparing 
with a control group. These results correspond with other studies where HRQOL was 
also investigated in IBD patients after attending group-based education programmes. 
No improvement in HRQOL was found in any of these studies, but the education 
programmes were highly appreciated by the patients [86, 89, 90, 113]. Another study 
found that a group-based education programme improved patient knowledge and 
patient satisfaction, but no improvement could be found in HRQOL here either [91]. 
Moser et al. found a significant correlation between patients’ worries and concerns and 
their perceived level of information. Lower scores of information level were associated 
with greater concerns [73].  
 
HRQOL is positively influenced by “providing information” [114], but several 
questions still remain about the best way of doing this. Being part of a group can 
provide support simply due to the group dynamic. In one study it could be shown that 
there was an improvement in emotional and social aspects of HRQOL after attending a 
support group [115]. There are some differences between this study and Study I in this 
thesis. They had meetings once a month for 24 months, while we had a total of only 
three meetings, once a week.  
 
The intervention group had better HRQOL scores immediately after attending the 
education programme. However, this improvement could not be found six months after 
the education programme. This short-term effect is similar to a result in a study that 
analyzed the effect of a comprehensive lifestyle modification programme using an 
intervention group and a control group [116]. A significant great improvement in Short-
Form 36 scale physical function and a significant great reduction in anxiety scores 
could be seen three months after the programme. An improvement could also be seen in 
the IBDQ scores, although not significant, but no significant differences between the 
intervention group and the control group were found after twelve months. In another 
study, a short-term effect could be detected when CD patients were given access to a 
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nurse-led counselling service. An improvement could be seen in HRQOL after six 
months but the effect was not sustained for 12 months [117]. 
 
In one study, disease-related information was found to result in deteriorated HRQOL 
[118], but the information was given in the form of information booklets and it may be 
ineffective to provide disease-related information without the opportunity to discuss 
questions or concerns that arise. Furthermore, the participants may not have bothered to 
read the information booklets. Another explanation for the fact that there was no 
improvement in HRQOL in either this study or our study might be that the patients 
were perhaps not in remission. Symptom severity is one of the most important 
associations with reduced HRQOL [4-7, 49, 53, 56-60].  
 
The education programme could readily be applied in the clinic. It was held at the 
hospital and lectures were given by the working staff, so rooms and lecturers were easy 
to organize. Even if no improvement could be found in HRQOL after attending a multi-
professional group-based education programme, the patients were positive and satisfied 
overall.  
 
8.2 PREDICTORS OF LOW HRQOL  
Study II showed that HRQOL was poorer for patients with short disease duration than 
for patients with long disease duration. There were no differences between CD and UC 
patients. However, a significant effect on the interaction between diagnosis and 
duration was found, indicating that patients with CD and short disease duration have 
the poorest HRQOL.  
 
These results contradict the results from another study where no differences in HRQOL 
could be found between CD patients with long disease duration and patients with short 
disease duration [9].  However, it is difficult to compare these results with those of 
Study II, since they compared patients who had been diagnosed less than 10 years 
earlier with patients whose diagnosis was more than 20 years old. The patients in the 
short-duration group in this study were comparable with the patients in the long-
duration group in Study II.  
 
Several studies have examined whether there are any differences in HRQOL between 
CD patients and UC patients. In Study II, no differences could be found between CD 
patients and UC patients when only diagnosis was considered. This correlates with 
other studies [5, 62, 63]. However, some studies have found that CD patients have 
poorer HRQOL [3, 8, 53, 61]. CD patients are more often in hospital compared with 
UC patients, and they also have more re-admissions [119]. Since CD and UC differ in 
several ways, for example in symptoms and complications, it makes sense not to treat 
the diseases in the same way, also with regard to giving disease-related information.  
 
Few studies have investigated whether there are differences in HRQOL due to disease 
duration. One study compared CD patients and UC patients in their first relapse with 
patients who had reported at least three relapses [65]. In contrast to Study II, no 
difference in HRQOL could be found, indicating that it is similar in debut and recurrent 
relapses for both CD patients and UC patients. However, the designs in the two studies 
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are very different, making it difficult to compare them. For example, for the patients in 
the group with several relapses, disease duration was five years at the most. In Study II, 
the mean number of years for disease duration of the patients in the long-duration group 
was 14 years for CD patients and 12 years for UC patients. As in Study II, other studies 
have found that patients with long disease duration have better HRQOL [5, 7, 120]. The 
most common course seems to be a decrease in symptoms over time [20, 21]. Since 
disease activity is the most important factor for decreased HRQOL, this may be one 
reason why the patients in the long-duration group had better HRQOL. However, here 
too, there are some contradictory findings. Etienney et al. examined CD patients and 
could find no evidence that CD activity burned out in time [121]. 
 
One study found that 20% of IBD patients expressed a need for psychotherapy. 
Anxiety, worries and short disease duration were some of the reasons for this [77]. 
Non-adherence is a common problem in IBD. Non-adherence increases when the 
patients are < 40 years old and have disease duration < 5 years. Poor adherence may 
result in more frequent relapses and a disabling disease course [83]. One way of 
increasing adherence is to give the patients disease-related education. Since the number 
of patients with IBD is increasing, it is important to know which patients have the 
greatest need of education. It is also important to gain more insight into which issues an 
education programme should concentrate on. In this way an education programme that 
focuses on the most important topics could be provided for a special patient group. The 
results in Study II suggest that it is newly diagnosed CD patients that need disease-
related education most. This correlates with a study that found an improvement in 
HRQOL in a group of IBD patients with disease duration ≤3 years after attending an 
education programme. No improvement in HRQOL could be found in patients with 
disease duration ≥ 3 years [90]. Bregenzer et al. also conclude that patients should be 
educated at the beginning of their disease in order to achieve the optimal effect [89].  
 
8.3 WORRIES AND CONCERNS  
IBD patients have many worries and concerns related to the disease. Worries and 
concerns about IBD may affect the patient’s adjustment and compliance to the illness 
[2]. Patients are influenced by the seesawing of their fears and hopes. This seems to be 
linked to what they know and what they do not know, and what cannot be known 
because of the nature of the illness [74]. Very few patients ask friends or neighbours for 
help when they need it. They either do not want people outside their closest family to 
know about their condition or they do not want to impose on people [122].  However, 
patients have also expressed a feeling of increasing the burden when discussing their 
worries and concerns with a family member [10].  It is important for healthcare 
professionals to recognize and address the worries and concerns that are important for 
the patient, not only the issues that the healthcare professionals feel are important. 
 
In both the clinical and the research setting it is essential to have validated instruments 
in order to assess and measure worries and concerns in IBD patients. A more detailed 
assessment of the worries and concerns provides useful information about HRQOL. 
Two IBD-specific questionnaires, the IBDQ and the RFIPC, have shown adequate 
validity and reliability. The RFIPC is better for reflecting the psychological and social 
aspects of IBD from the patient’s point of view, while the IBDQ provides a better 
 28 
reflection of disease activity [123]. Therefore, when measuring worries and concerns in 
IBD, the RFIPC is the most appropriate choice. 
 
In Study III, the factor structure of the Swedish version of the RFIPC was validated. 
The study focused on validation of the factor structure that was suggested by Drossman 
[1], with a differentiation of the components of worries. In Sweden the RFIPC is most 
often used by reporting the sum score or ranking the items [4, 58, 124]. The results in 
Study III suggest that use of a single-factor model (sum score) of the RFIPC is an 
unacceptable structure of this measure. This model suggests that a single underlying 
uni-dimensional latent variable of the patient’s worries is manifested in the items of the 
RFIPC. No matter what the worries and concerns are about, the patient is characterized 
by a degree of worries and concerns. Study III displayed that a slightly modified model 
of the original factor structure of RFIPC had the most acceptable fit. In this version, the 
patient’s worries and concerns can be divided into distinct components: impact of 
disease, sexual intimacy, complications, and body stigma. To be able to address worries 
and concerns in clinical practice it is important to know specifically what each patient 
is worried about. This approach provides more nuanced data and useful information in 
both clinical and research settings. Healthcare professionals gain information about 
what each patient is worried about and this enables them to provide the patient with 
appropriate education and support. Using the RFIPC by reporting each item and/or 
ranking the items is another method, although in this way it may be difficult to get an 
overview of patients’ worries and concerns. The factorial structure according to 
Drossman that was replicated in Study III makes it easier to gain information in a 
clinical setting about which issues are most worrying for each patient. It also provides 
important data in subgroups of patients. Some may have worries related to 
complications, while another subgroup may worry about the impact of the disease.  In 
Study III, significantly greater worries and concerns in the factor impact of disease 
were reported by CD patients than by UC patients. These findings give more detailed 
information about patients’ worries and concerns compared with using a sum score or 
ranking of items.  
   
The RFIPC has been validated in Sweden, both in UC patients [125] and in CD patients 
[126]. In the study with CD patients, an exploratory factor analysis was conducted and 
four factors similar to those of Study II and Drossman were found. However, in some 
ways the factors are different from Drossman’s original factors. In this study, the 
factors complications, achievements, intimacy, and stigma were found. A Norwegian 
study also validated the RFIPC using exploratory factor analysis [127], finding six 
factors, only one of which, sexual intimacy, was identical to a factor in Drossman’s 
original validation. Another study that conducted an exploratory factor analysis could 
not distinguish any factors in the RFIPC questions [128]. It was therefore concluded 
that no interpretation of answers regarding different aspects of patient concerns could 
be made. 
 
Study III also displayed significant correlations between the factors of RFIPC and the 
factors of IBDQ (bowel symptoms, systemic symptoms, social function, and emotional 
function) and the HI. Furthermore, the findings showed that social function is 
associated with worries concerning impact of disease and sexual intimacy but not with 
   29 
complications or body stigma. The results also suggest that bowel symptoms are 
unrelated to worries about complications.  
 
The more detailed assessment provided by using the factorial structure of the RFIPC, as 
suggested by Drossman and replicated in Study III, gives more detailed information 
about disease-related worries and concerns of IBD patients in both research and clinical 
settings, as these components of worries are differently related to HRQOL and general 
health.  
 
8.4 STRESS AS A TRIGGER FACTOR 
Study IV showed that perceived acute stress can be considered as a trigger factor for 
relapses in IBD. Patients with IBD believe that the severity of the disease is affected by 
stress and their attitude to life [10]. Levels of stress and the nature of what is stressful 
are very similar for patients with IBD and healthy controls [129]. Those in remission 
even reported lower levels of daily stress compared with the healthy controls. This may 
reflect a positive rebound effect of having some relief from the disease [129]. Also, the 
use of active coping strategies to deal with stress is similar no matter whether an 
individual suffers from IBD or not [130].  
 
Studies that examined the association between stress and relapses in IBD are 
inconclusive. Some studies have found that stressful life events do not trigger relapses 
in IBD [42, 43, 131]. In studies where no association between stress and relapses in 
IBD has been found, it is most often stressful life events that are investigated. However, 
other studies have shown that perceived stress may trigger a relapse in IBD [35-38]. 
Bernstein et al. examined both stressful life events and perceived stress, and found that 
both could be considered as trigger factors for relapses in IBD [35]. Mawdsley et al. 
displayed that experimental stress causes increases in a range of inflammatory 
variables. Each of these variables may contribute to cause relapses in IBD [39]. 
  
It has also been suggested that studies of stress should analyze CD and UC separately 
[41, 45]. UC has more often proved to be a trigger of relapses than CD. This might be 
due to difficulties in defining clear criteria for relapses and remission in CD [41]. This 
contradicts the results from Study IV where the trigger effect of stress seemed to be 
higher in CD patients. Bitton et al. were also able to show that high stress influenced 
relapse in CD patients [36]. 
 
In Study IV, high levels of stress are found to increase the risk of relapse the next day. 
This contradicts the results of Levenstein et al., where it is rather long-term perceived 
stress that is considered as a trigger factor [38]. The patients were followed for 45 
months or until the patient experienced a relapse. Relapse status could be monitored for 
up to 68 months. In this study, no increase in stress levels just before a relapse could be 
found. The results suggest 8-11 months before symptoms began. Levenstein et al. also 
conclude that it is perceived stress that appears to be a trigger factor for relapses and not 
stressful life events or depressive symptoms. A strength of this study is that the patients 
were followed with proctoscopy to establish the relapses. Examination with 
proctoscopy not only identifies the relapses, but also classifies them in normal mucosa, 
minimal, mild, moderate, or severe activity. In Study IV, the relapses were identified 
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according to symptoms that the patients stated in the diary. Patients’ files were however 
scrutinized after the data collection in order to check the identified relapses. But since 
not all patients seek hospital care when they have a relapse, this method does not 
provide complete information. Eighteen of the 42 identified relapses had not been 
recorded in the hospital. This does not mean that the patients did not have real relapses. 
Often patients with IBD start a treatment on their own without contacting the IBD 
clinic. Another difference between these studies is the duration of disease. In Study IV, 
patients with disease duration of less than two years were included, while the patients in 
the study by Levenstein had a mean disease duration of 6.5 years. Patients with a 
chronic disease and with long disease duration may have changed some factors in their 
way of life in order to feel better. There may therefore be some difficulties in 
examining and comparing patients with different disease duration. In Study IV, patients 
were followed on a daily basis, whereas patients were followed monthly in the study by 
Levenstein. This difference in design could also explain the differences in result. In 
Study IV, patients were only followed for six months and therefore no long-term effects 
could be examined.  
 
It is also unclear whether stress management programmes have an effect in reducing 
relapses. Stress management psychotherapy does not improve disease activity or 
disease course in IBD patients [46]. However, one study found that patients who 
received a brief behavioural intervention, targeting stress and disease self-management 
experienced a reduction in risk of relapse [132]. One study gave 60 patients with UC a 
structured training programme which included stress management training. The use of 
relaxing techniques proved to be a significant predictor of improvement in the 
psychological sum score after three months of therapy [116]. 
 
The strength of Study IV is its design. The patients acted as their own controls and 
were followed on a daily basis during a period of six months. The case-crossover 
design eliminates all confounding factors.  
 
8.5  METHODOLOGICAL CONSIDERATIONS 
In Study I, all patients were in remission at baseline. In order to examine if the patients 
were still in remission at the six-month measurement, the patients’ files were 
scrutinized. The investigation showed that 42% in the intervention group and 22% in 
the control group had relapsed or had symptoms of their disease. Disease activity 
influences the HRQOL negatively, and this may have made it difficult to measure 
HRQOL after six months and compare with the baseline measurement. 
 
In Study I, it is possible that it is not HRQOL that should be measured to evaluate an 
education programme. Instead it may be the patient’s worries and concerns or 
knowledge score that should be measured.  
 
In Study III, the analysis is performed in a single primary sample. Therefore it is not 
cross-validated. To establish the results more firmly, a cross-validation of the suggested 
factor structure of the RFIPC in other samples is advisable.  
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In Study III, correlated error terms were included. This is generally not recommended, 
but correlation of error terms of these items was considered appropriate. For example, 
having an ostomy bag is associated with surgery, and the fear of dying early can be 
related to developing cancer.  
 
One limitation in Study IV is the small number of patients. It is difficult to include 
patients in a study where they are asked to fill in a diary on a daily basis. Even if the 
diary was easy to fill in, and only took about one minute per day, several patients felt it 
was too much work and did not want to participate.  
 
In Study IV, the patients were asked about their perceived stress in only one question. 
Other studies that measured perceived stress have used validated questionnaires [35-
38]. We chose the one single question since we wanted to measure the presence and 
degree of perceived stress on a daily basis during a period of six months. Under these 
circumstances it is imperative to use an easy and fast instrument for the patients to fill 
in, otherwise they might drop out.  
 
Another limitation in Study IV was the risk of recall bias. If the patients forgot to fill in 
the diary one day they might have done it retrospectively. However, this retrospective 
reporting is most likely when there was no variation in the reported variables. If 
symptoms were present or if some factors in life were unusual, patients would probably 
have been reminded of the study that they were included in. Nevertheless, in spite of 
the potential for misclassification due to memory recall, the strength of the design is 
that the patients did not know about the definition of relapse or the time periods of 
interest.  
 
Of the potential trigger factors included in the diary in Study IV, it was only stress that 
displayed an effect. Diet, smoking, infections, and antibiotics did not show an effect. 
The sample size was small and difficulties in measuring, for example, diet may be one 
reason for the non-effect. The patients were asked to fill in if they had more or less 
sugar, fat, and/or fibre compared with their normal food intake. In the diary there was 
an explanation of what sugar, fat and fibre could be classified as. But it might 
nevertheless have been a problem for them to interpret the information and give an 
adequate answer. 
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9 CONCLUSION  
 
A multi-professional group-based education programme could readily be applied in the 
clinic. Patients had improved RFIPC scores immediately after the education 
programme, although when comparing with the control group, no improvement could 
be seen in HRQOL at the six-month follow-up. The education programme was  highly 
appreciated by the patients. 
 
HRQOL is poorer for patients with short disease duration than for patients with long 
disease duration. No differences could be found between CD and UC patients. Patients 
with CD and short disease duration have the poorest HRQOL. 
 
The factorial structure of the RFIPC as suggested by Drossman [1] was replicated in a 
Swedish version. The four separate factors identified in this structure provide more 
detailed information about disease-related worries and concerns of IBD patients than 
the sum score. 
 
Perceived stress may act as a trigger for relapses in IBD. A high level of stress one day 
increases the risk of relapse the next day. 
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10 CLINICAL IMPLICATIONS AND FUTURE STUDIES 
 
10.1 CLINICAL IMPLICATIONS 
No improvement could be found in HRQOL after attending an education programme, 
but the patients were positive and satisfied overall. They became better informed about 
how to manage their disease. The increased knowledge may improve compliance, and 
lead to a better understanding of treatment, and, by extension, to fewer relapses.  
 
Patients with CD and short disease duration have the lowest HRQOL and are in most 
need of education and support. It is important for healthcare professionals to identify 
patients with the greatest need for education and support, in order to develop effective 
nursing intervention programmes. The more detailed version of the RFIPC may help to 
provide each patient with the appropriate education and support. 
 
By identifying potential trigger factors for relapses in IBD there is also a potential for 
preventing relapses by influencing for example stress levels and optimizing the clinical 
care of these patients. 
 
10.2 FUTURE STUDIES 
Further investigations with larger power are needed to confirm the findings regarding 
stress as a trigger for relapses in IBD. The case-crossover design is a valuable method 
and the structured diary would be a useful tool in further studies. 
 
Further investigations are needed to examine the worries and concerns of IBD patients 
in order to develop more adequate intervention programmes. The RFIPC with four 
factors is a useful tool for future studies. There is also a need for more qualitative 
studies in order to more deeply examine HRQOL, as well as the worries and concerns 
of IBD patients. 
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11 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Inflammatorisk tarmsjukdom (Inflammatory Bowel Disease=IBD) är en 
sjukdomsgrupp som omfattar sjukdomarna Crohns sjukdom och ulcerös colit. Dessa är 
kroniska sjukdomar som går i skov (sjukdomsattacker). De vanligaste symtomen är 
diarré, blodtillblandad avföring, buksmärtor, trötthet och viktnedgång. Vanligaste 
åldern att insjukna är 15-35 års ålder. Varför man får IBD är ännu okänt men man tror 
att det är en kombination av flera faktorer. Hur sjukdomsbilden ska komma att se ut och 
hur ofta en patient med IBD kommer att få skov är okänt. Stress verkar dock vara en 
potentiell så kallad triggerfaktor till skov i IBD.  
 
Patienter med IBD måste anpassa sig till en livslång sjukdom och göra många 
anpassningar i livet. Studier har visat att de har en sämre hälsorelaterad livskvalitet 
(Health-Related Quality of Life=HRQOL) jämfört med en frisk population. Det som 
påverkar HRQOL mest negativt är skov i sjukdomen. Patienter med IBD känner också 
mycket oro relaterat till sjukdomen. Det som ger mest oro är relaterat till kirurgi, 
energinivå, att få en påse på magen, osäkerhet kring sjukdomens natur, effekt av 
medicinering, att bli en börda för andra, tappa kontroll över tarmen och att utveckla 
cancer. 
 
Patienter med kroniska sjukdomar som IBD behöver kunskap om sjukdomen samt hur 
den ska hanteras. Att vara väl utbildad inom sin sjukdom kan ge en positiv påverkan på 
HRQOL samt en god kapacitet till att hantera sin behandling.   
 
Det övergripande syftet med denna avhandling var att samla vetenskaplig fakta om oro 
och bekymmer, HRQOL och triggerfaktorer till skov samt att skapa och utvärdera ett 
utbildningsprogram. 
 
Syftet med delstudie I var att skapa ett utbildningsprogram anpassat till 
nydiagnostiserade patienter med IBD och som lätt kunde appliceras på kliniken samt att 
undersöka om ett gruppbaserat utbildningsprogram kan förbättra HRQOL hos patienter 
med IBD. 93 patienter med Crohns sjukdom eller ulcerös colit deltog i studien. Hälften 
lottades till en interventionsgrupp och fick delta i ett gruppbaserat utbildningsprogram 
medan hälften lottades till en kontrollgrupp. HRQOL mättes med hjälp av fyra 
frågeformulär som fylldes i när de inkluderades i studien samt efter sex månader. 
Interventionsgruppen fyllde dessutom i frågeformulären efter en månad (direkt efter 
avslutat utbildningsprogram). Ingen skillnad framkom i HRQOL mellan 
interventionsgrupp och kontrollgrupp vid mätningen efter sex månader. 
Interventionsgruppen hade dock förbättrade värden i HRQOL vid mätningen efter en 
månad, direkt efter utbildningsprogrammet. Det gruppbaserade utbildningsprogrammet 
var uppskattat av patienterna. 
 
Syftet med delstudie II var att identifiera vad som kan förutsäga nedsatt HRQOL hos 
patienter med IBD samt göra en jämförelse mellan Crohns sjukdom och ulcerös colit 
och med sjukdomsduration. 197 patienter med Crohns sjukdom eller ulcerös colit 
deltog i studien. De fyllde i fyra frågeformulär som mätte HRQOL vid ett tillfälle. 
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Ingen skillnad i HRQOL framkom mellan patienter med Crohns sjukdom och patienter 
med ulcerös colit. Patienter med kort sjukdomsduration (< 2 år) hade sämre HRQOL 
när de jämfördes med patienter med lång sjukdomsduration (> 5 år). De som hade 
sämst HRQOL var patienter med Crohns sjukdom och kort sjukdomsduration. 
 
Syftet i delstudie III var att utvärdera frågeformuläret Rating Form of Inflammatory 
Bowel Disease Patient Concerns (RFIPC) utifrån svenska förhållanden. 195 patienter 
med Crohns sjukdom eller ulcerös colit deltog i studien. De fyllde i RFIPC samt 
ytterligare två frågeformulär vid ett tillfälle. RFIPC används för att mäta oro och 
bekymmer hos patienter med IBD. Det innehåller 25 områden angående oro relaterat 
till IBD. Dessa områden kan till exempel handla om ”att bli opererad”, ”att få cancer”, 
”att kunna få barn”, ”att lukta illa”. RFIPC används i Sverige men oftast utan att 
använda den struktur som förslogs i originalversionen. Där delades de 25 områdena in i 
fyra faktorer medan i Sverige räknas oftast en totalsumma på alla områden. Resultatet i 
delstudien visar otydliga anpassningsmått då RFIPC används med totalsumma. 
Originalversionen, med lätt förändring, visade det bästa anpassningsmåttet.  
 
Syftet med delstudie IV var att undersöka om upplevd stress kan starta ett skov i IBD. 
60 patienter med Crohns sjukdom eller ulcerös colit deltog i en dagboksstudie. 
Dagboken innehöll frågor angående symtom i deras sjukdom samt en fråga om stress. 
Patienterna fyllde i dagboken varje dag under sex månader. Analyserna visade att hög 
grad av stress en dag kan öka risken för skov dagen efter. 
 
Sammanfattning 
Ingen förbättring i HRQOL framkom efter att patienterna deltagit i ett gruppbaserat 
utbildningsprogram. Utbildningen var dock uppskattad av patienterna. Patienter med 
Crohns sjukdom och kort sjukdomsduration har sämst HRQOL och har störst behov av 
utbildning och stöd. Genom att använda frågeformuläret RFIPC med de fyra faktorerna 
som föreslagits i originalversionen ges en mer detaljerad information om patienternas 
sjukdomsrelaterade oro både i forskningssammanhang och i den kliniska vården. Detta 
kan hjälpa sjukvårdspersonalen att erbjuda varje enskild patient lämplig utbildning och 
stöd. Det som försämrar HRQOL mest negativt är skov. Att identifiera faktorer som 
triggar skov ger en möjlighet att också om möjligt påverka denna trigger. Hög grad av 
stress verkar kunna öka risken för skov.  
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